EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 68 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $238,762 | -18.0% | 12,282 | +11.5% | 0.00% | -50.0% |
| Q3 2022 | $291,000 | -7.6% | 11,012 | +55.3% | 0.00% | 0.0% |
| Q2 2022 | $315,000 | -10.3% | 7,090 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $351,000 | -2.8% | 7,090 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $361,000 | -8.6% | 7,090 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $395,000 | -42.4% | 7,090 | -55.7% | 0.00% | -50.0% |
| Q2 2021 | $686,000 | +5616.7% | 16,022 | +5443.9% | 0.00% | – |
| Q1 2021 | $12,000 | -98.2% | 289 | -97.9% | 0.00% | -100.0% |
| Q4 2020 | $653,000 | +9.6% | 14,025 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $596,000 | -14.5% | 14,025 | -3.4% | 0.00% | 0.0% |
| Q2 2020 | $697,000 | -63.4% | 14,517 | -64.9% | 0.00% | -69.2% |
| Q1 2020 | $1,904,000 | -70.8% | 41,390 | -61.8% | 0.01% | -56.7% |
| Q4 2019 | $6,513,000 | +20.9% | 108,414 | +13.8% | 0.03% | +20.0% |
| Q3 2019 | $5,388,000 | -1.7% | 95,246 | -3.2% | 0.02% | 0.0% |
| Q2 2019 | $5,481,000 | -7.3% | 98,443 | -15.9% | 0.02% | -3.8% |
| Q1 2019 | $5,910,000 | +119.8% | 117,045 | +75.4% | 0.03% | +100.0% |
| Q4 2018 | $2,689,000 | -34.4% | 66,731 | +12.9% | 0.01% | -13.3% |
| Q3 2018 | $4,099,000 | +30.0% | 59,120 | +41.8% | 0.02% | +15.4% |
| Q2 2018 | $3,153,000 | -43.6% | 41,679 | -41.1% | 0.01% | -40.9% |
| Q2 2017 | $5,586,000 | +19.1% | 70,806 | +25.2% | 0.02% | +10.0% |
| Q1 2017 | $4,692,000 | +2.4% | 56,566 | -2.1% | 0.02% | -4.8% |
| Q4 2016 | $4,583,000 | +14.7% | 57,761 | +1.2% | 0.02% | +10.5% |
| Q3 2016 | $3,994,000 | +29.5% | 57,057 | -28.3% | 0.02% | +26.7% |
| Q2 2016 | $3,085,000 | -0.4% | 79,540 | +4.0% | 0.02% | 0.0% |
| Q1 2016 | $3,098,000 | +1.0% | 76,502 | +121.1% | 0.02% | 0.0% |
| Q4 2015 | $3,068,000 | +54.4% | 34,601 | +28.9% | 0.02% | +50.0% |
| Q3 2015 | $1,987,000 | +10.4% | 26,841 | +20.6% | 0.01% | +11.1% |
| Q2 2015 | $1,800,000 | +255.0% | 22,263 | +84.0% | 0.01% | +200.0% |
| Q1 2015 | $507,000 | – | 12,099 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |